ONCOseeker™ Solid​

Cancer diagnostic NGS kit using hybridization capture method

ONCOseeker™ Solid is a hybridization capture-based solid cancer diagnostic panel that provides patient prognosis prediction and diagnostic information.

Based on next-generation sequencing (NGS) technology, our panel provides optimal treatment information for cancer patients in a short time with a single test and predicts the course of the disease after treatment, helping to customize treatment.

Introduction

Cell-free DNA or gDNA from FFPE

*FFPE : Formalin Fixed Paraffin Embedded tissue

ONCOseeker™ is a solid cancer diagnostic panel based on a hybridization capture method that provides prediction and diagnosis information for patients. Not only gDNA extracted from FFPE and cell-free DNA extracted from blood can be applied to the panel.

Hybridization capture using a probe

A panel system that detects mutant genes using the characteristics of biotin, which has a specific binding to probes. It can check the target’s mutation by using a probe that specifically binds to the target region. A DNA, bound to the probe can be captured using a magnetic bead.

Next Generation Sequencing (NGS) & Analysis

A library captured by using beads is available with enrichment through PCR. The amplified library is generated from ONCOseeker™ panel data through NGS sequencing equipment. The data can be analyzed through GeneCker’s in-house database analysis program, PinAnalysis™.

Lineup

ONCOseeker™ Solid is an NGS (Next-generation sequencing) based solid cancer diagnostic panel with a hybridization capture method of major genetic mutations related to solid tumors. It consists of 45 genes specialized for solid cancer patients following clinical diagnosis guidelines to detect various genetic mutations and provide an accurate high-quality analysis.

ONCOseeker™ Solid is a small-medium size and can be used not only in big hospitals but also in small hospitals. Based on clinical evidence, it provides optimal treatment and drug information in a short period. Also, it can predict the progress (prognosis) of the disease after treatment for customized treatment.

Product Specification

ONCOseeker™ Solid
Input DNA FFPE 200 ng
cell free DNA 20 ng
Target enrichment Hybridization-captured
Platform Illumina MiSeqDx
MiSeq reagent v2 or v3
Target Size Size : 144 kb
Gene : 45
Applications Indel, SNV, CNV
Library prep time ≤ 2~2.5 days
Analysis solution PinAnalysis™
Target Hotspot List
AKT1 BRIP1 FANCL KIT NRAS SMAD4
ALK CDK12 FBXW7 KRAS PALB2 SMARCA4
APC CDKN2A FGFR2 MDM2 PDGFRA SMARCB1
AR CHEK2 FGFR3 MET PIK3CA STK11
ATM CTNNB1 GNAS MTOR PTEN TP53
BRAF EGFR HRAS MYC PTPN11
BRCA1 ERBB2 IDH1 MYCN RET
BRCA2 ESR1 IDH2 NF1 ROS1

Performance evaluation

Total Specification
Sensitivity 100%
Specificity 100%
Accuracy PPA 90% (Positive Percentage Agreement)
PPV 100% (Positive Predictive Value)
LOD SNV 1.0% VAF
(Limit Of Detection)
INDEL 1.0% VAF
SNV PPA 96.4% (Positive Percentage Agreement)
PPV 100% (Positive Predictive Value)
INDEL SNV 84.2% (Positive Percentage Agreement)
INDEL 100% (Positive Predictive Value)

Library preparation process